No, I Am Spartacus – Embecta Joins The Quell Against GLP-1 Hype

Embecta, which recently completed its spin-off from Becton Dickinson, is forging ahead with its insulin injector-based business strategy, GLP-1s be damned. 

• Source: Shutterstock

More from Diabetic Care

More from Device Area